Levodopa gains psychostimulant-like properties after nigral dopaminergic loss.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 23494678.
- Also identified by DOI 10.1002/ana.23881.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Dopamine dysregulation syndrome shares some core behavioral features with psychostimulant addiction, suggesting that dopamine replacement therapy can acquire psychostimulantlike properties in some patients with Parkinson disease (PD). We here report strong experimental evidence supporting this hypothesis in an α-synuclein rat model of PD. Although levodopa had no effect in controls, it acquired 2 prominent psychostimulantlike properties in Parkinsonian rats: (1) it produced intense reward on its own and in parallel (2) decreased interest in other nondrug reward. These 2 effects may combine to explain the addictive use of levodopa after loss of midbrain dopamine neurons in some PD patients.
Medical subject headings
- Antiparkinson Agents
- Dopaminergic Neurons
- Levodopa
- Parkinson Disease
- Substantia Nigra